The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though? Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Viking Therapeutics, Inc. (VKTX) . Viking Therapeutics currently ...

The new drugs this company is developing could be worth a lot more than the present market value of its stock. Shares of Viking Therapeutics (VKTX 0.43%), a clinical-stage drugmaker working on metabolic treatments, have tripled in value this year. Despite the huge run-up, analysts who follow the company think it has heaps more upside. The average analyst who follows Viking Therapeutics thinks it can rise to $113.55 per share. Reaching the consensus expectation would result in a gain of about 76% from the st ...

Shares of Viking Therapeutics (VKTX) have soared nearly 25% in the past month, all thanks to progress with its investigational obesity and non-alcoholic steatohepatitis (NASH) candidates, which management plans to advance to late-stage development by early 2025. Last month, alongside its second-quarter earnings results, VKTX reported that it had received feedback from the FDA regarding the next steps in the developmental pathway for the obesity drug VK2735. Based on such feedback, the company is gearing up ...

What Does Viking Therapeutics Do? Viking Therapeutics (VKTX) is a company that develops treatments for metabolic and endocrine disorders. VKTX's focus is on creating medication to address conditions such as steatohepatitis (NASH), a liver disease, as well as obesity and diabetes. Through its expertise in receptor signaling pathways, Viking Therapeutics strives to create therapies that cater to the needs of individuals facing these health challenges, ultimately aiming to improve outcomes over time. America h ...

Given this biotech's ascent, its odds of becoming a giant are better than most. The much-feted biotech Viking Therapeutics (VKTX -0.51%) is aiming for Novo Nordisk's (NVO -1.58%) cash cow, the market for weight loss drugs. If its ambitions are fulfilled, it has a shot at becoming as large as its big pharma rival. To see why this possibility is more than a pipe dream, let's start by making some quick calculations. That will help us to understand Viking's chances of becoming the next Novo Nordisk, based on ho ...

Zealand Pharma is the more experienced player In that vein, Viking Therapeutics (VKTX -7.17%) and Zealand Pharma (ZLDP.F -2.44%) are among the best biotechs aiming to enter the cardio-metabolic space in the next few years. Here's how they shape up in a headto-head comparison. That implies that Viking might not need to manufacture as much of its candidate to meet demand, which is an advantage. Furthermore, the side-effect profile is similar to the reigning champions, but, importantly, patients can in theory ...

One preliminary piece of evidence is sending its shares higher. Viking Therapeutics (VKTX 2.01%) just gave shareholders a few more reasons to be excited for the future. With its shares soaring by a stunning 34% on July 25 thanks to second-quarter earnings, the bull thesis for its continued outperformance is stronger than ever. It's clear now that the biotech has what it'll need to take on powerful competitors like Eli Lilly and Novo Nordisk. Here's why. Strong clinical data and minimal expenditures make a v ...

All of this has pushed shares of Viking to major gains this year, with performance even surpassing that of AI powerhouse Nvidia. Viking is developing injectable and oral GIP and GLP-1 receptor agonists, treatments that act on hormones controlling blood sugar levels and appetite. Just last week, the company said it's advancing VK-2735, its injectable candidate, into a phase 3 trial and has scheduled an end-of-phase 2 meeting with the U.S. Food and Drug Administration for later this year. In the phase 2 trial ...

Among the hottest investments these days are pharma and biotech companies that make weight loss drugs. Demand for these products surpasses supply, and analysts predict that sales growth for the new classes of effective treatments is just getting started. According to a forecast by Goldman Sachs Research, the global weight loss drug market may multiply by a factor of 16 to reach $100 billion by the end of the decade. Unlike Eli Lilly and Novo Nordisk, Viking is a clinical-stage company. It doesn't have any p ...

Viking Therapeutics Today VKTX Viking Therapeutics $69.04 +18.63 (+36.96%) 52-Week Range $8.28 ▼ $99.41 Price Target $111.56 Add to Watchlist Viking Therapeutics NASDAQ: VKTX is a clinical-stage biopharmaceutical company known for its focus on developing novel treatments for metabolic and endocrine disorders. Viking Therapeutics' earnings report for the second quarter of 2024 was impressive, capturing the attention of investors and the Viking Therapeutics' analyst community. Following the release of its ear ...